Downregulation of immune response by the human cytokines Interleukin-32α and β in cell-mediated rejection

Cellular Immunology

Volumn 264, Issue 1, 2010, Pages 47-53

  Chae, Jung Il ^b   Shim, Jung Hyun ^b   Lee, Kwang Su ^a   Cho, Young Sik ^c   Lee, Kyu Sun ^d   Yoon, Do Young ^e   Kim, Soo Hyun ^e   Chung, Hyung Min ^f,g   Koo, Deog Bon ^h   Park, Chang Sik ^a   Lee, Dong Seok ⁱ   Myung, Pyung Keun ^a  

^a Chungnam National University   (South Korea)

^b Chonbuk National University   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Konkuk University   (South Korea)

^f CHA Bio and Diostech Co Ltd   (South Korea)

^g CHA University   (South Korea)

^h Daegu University   (South Korea)

ⁱ Kyungpook National University   (South Korea)

Author keywords

Cytokines; IL 32 ; IL 32 ; Immune system; Pig; Xenograft rejection; Xenotransplantation

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 32; INTERLEUKIN 32ALPHA; INTERLEUKIN 32BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; GRAFT REJECTION; HOST CELL; IMMUNE RESPONSE; KIDNEY CELL; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; XENOTRANSPLANTATION;

ANIMALS; CELL LINE; CELL SURVIVAL; CELL TRANSPLANTATION; CLONING, MOLECULAR; EPITHELIAL CELLS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOMODULATION; INTERLEUKINS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C57BL; SWINE; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS;

MUS; SUIDAE; SUS;

EID: 77954145404     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.04.010     Document Type: Article

References (45)

1. Cascalho M., Platt J.L. The immunological barrier to xenotransplantation. Immunity 2001, 14:437-446.
2. Remuzzi G. Xenotransplantation: a challenge for the future of transplant medicine. Schweiz Med. Wochenschr. 1998, 128:952-960.
3. Samstein B., Platt J.L. Physiologic and immunologic hurdles to xenotransplantation. J. Am. Soc. Nephrol. 2001, 12:182-193.
4. Hammer C. Xenotransplantation: the good, the bad, and the ugly or how far are we to clinical application?. Transplant. Proc. 2003, 35:1256-1257.
5. Ahn C., Kim J.Y., Lee B.C., Kang S.K., Lee J.R., Hwang W.S. The past Present, and future of xenotransplantation. Yonsei Med. J. 2004, 45:1017-1024.
6. Logan J.S. Prospects for xenotransplantation. Curr. Opin. Immunol. 2000, 12:563-568.
7. Davila E., Byrne G.W., LaBreche P.T., McGregor H.C., Schwab A.K., Davies W.R., Rao V.P., Oi K., Tazelaar H.D., Logan J.S., McGregor C.G. T-cell responses during pig-to-primate xenotransplantation. Xenotransplantation 2006, 13:31-40.
8. Sebille F., Dorling A., Lechler R.I. The cellular rejection of xenografts-recent insights. Xenotransplantation 2003, 10:4-6.
9. Shimizu A., Yamada K. Pathology of renal xenograft rejection in pig to non-human primate transplantation. Clin. Transplant. 2006, 20(Suppl 15):46-52.
10. Pierson R.N., Winn H.J., Russell P.S., Auchincloss H. Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J. Exp. Med. 1989, 170:991-996.
11. Fox A., Mountford J., Braakhuis A., Harrison L.C. Innate and adaptive immune responses to nonvascular xenografts: evidence that macrophages are direct effectors of xenograft rejection. J. Immunol. 2001, 166:2133-2140.
12. Dorling A., Riesbeck K., Warrens A., Lechler R. Clinical xenotransplantation of solid organs. Lancet. Lancet 1997, 349:867-871.
13. Fox A., Harrison L.C. Innate immunity and graft rejection. Immunol. Rev. 2000, 173:141-147.
14. Hong J., Bae S., Kang Y., Yoon D., Bai X., Chan E.D., Azam T., Dinarello C.A., Lee S., Her E., Rho G., Kim S. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine 2010, 49:171-176.
15. Felaco P., Castellani M.L., De Lutiis M.A., Felaco M., Pandolfi F., Salini V., De Amicis D., Vecchiet J., Tete S., Ciampoli C., Conti F., Cerulli G., Caraffa A., Antinolfi P., Cuccurullo C., Perrella A., Theoharides T.C., Conti P., Toniato E., Kempuraj D., Shaik Y.B. IL-32: a newly-discovered proinflammatory cytokine. J. Biol. Regul. Homeost. Agents 2009, 23:141-147.
16. Netea M.G., Azam T., Ferwerda G., Girardin S.E., Walsh M., Park J.S., Abraham E., Kim J.M., Yoon D.Y., Dinarello C.A., Kim S.H. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc. Natl. Acad. Sci. USA 2005, 102:16309-16314.
17. Joosten L.A., Netea M.G., Kim S.H., Yoon D.Y., Oppers-Walgreen B., Radstake T.R., Barrera P., van de Loo F.A., Dinarello C.A., van den Berg W.B. IL-32, A proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 2006, 103:3298-3303.
18. Kim C.J., Cho Y.G., Park Y.G., Nam S.W., Kim S.Y., Lee S.H., Yoo N.J., Lee J.Y., Park W.S. Pin1 overexpression in colorectal cancer and its correlation with aberrant beta-catenin expression. World J. Gastroenterol. 2005, 11:5006-5009.
19. Shoda H., Fujio K., Yamaguchi Y., Okamoto A., Sawada T., Kochi Y., Yamamoto K. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res. Ther. 2006, 8:R166.
20. Kim S.H., Han S.Y., Azam T., Yoon D.Y., Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005, 22:131-142.
21. Hill G.R., Cooke K.R., Teshima T., Crawford J.M., Keith J.C., Brinson Y.S., Bungard D., Ferrara J.L. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 1998, 102:115-123.
22. Choi Y.S., Kim Y.K., Shim J.H., Kim E.M., Kang H.S., Yoon do Y., Muneta Y., Myung P.K. Immunosuppression of xenograft rejection in porcine kidney PK15 cells by porcine IL-18. Exp. Mol. Med. 2006, 38:574-582.
23. Kim K.H., Shim J.H., Seo E.H., Cho M.C., Kang J.W., Kim S.H., Yu D.Y., Song E.Y., Lee H.G., Sohn J.H., Kim J., Dinarello C.A., Yoon D.Y. Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. J. Immunol. Meth. 2008, 333:38-50.
24. Schwarz M.R. The mixed lymphocyte reaction: an in vitro test for tolerance. J. Exp. Med. 1968, 127:879-890.
25. Cooke K.R., Gerbitz A., Crawford J.M., Teshima T., Hill G.R., Tesolin A., Rossignol D.P., Ferrara J.L. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J. Clin. Invest. 2001, 107:1581-1589.
26. Teshima T., Hill G.R., Pan L., Brinson Y.S., Brinson Y.S., van den Brink M.R., Cooke K.R., Ferrara J.L. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 1999, 104:317-325.
27. Decker T., Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Meth. 1988, 115:61-69.
28. Seidel M.G., Freissmuth M., Pehamberger H., Micksche M. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 358:382-389.
29. Parker W., Saadi S., Lin S.S., Holzknecht Z.E., Bustos M., Platt J.L. Transplantation of discordant xenografts: a challenge revisited. Immunol. Today 1996, 17:373-378.
30. Moses R.D., Pierson R.N., Winn H.J., Auchincloss H. Xenogeneic proliferation and lymphokine production are dependent on CD4+ helper T cells and self antigen-presenting cells in the mouse. J. Exp. Med. 1990, 172:567-575.
31. Smyth M.J., Sutton V.R., Kershaw M.H., Trapani J.A. Xenospecific cytotoxic T lymphocytes use perforin- and Fas-mediated lytic pathways. Transplantation 1996, 62:1529-1532.
32. Zhang Z., Zhu L., Quan D., Garcia B., Ozcay N., Duff J., Stiller C., Lazarovits A., Grant D., Zhong R. Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation 1996, 62:1267-1272.
33. Uff C.R., Reid S.D., Wood R.F., Pockley A.G. CD44 expression in rejecting rat small bowel allografts. Transplantation 1995, 60:985-989.
34. Krishnan R., Kireta S., Carter J.K., Grooby W.L., Rao M.M., Russ G.R. Expression of alternatively spliced CD44 mRNA in sheep renal allografts. Transplant. Proc. 1995, 27:2170-2171.
35. Wells A., Larsson E., Hanas E., Laurent T., Hallgren R., Tufveson G. Increased hyaluronan in acutely rejecting human kidney grafts. Transplantation 1993, 55:1346-1349.
36. Sugiyama K., Komada Y., Deguchi T., Zhang X.L., Azuma E., Ido M., Yamamoto H., Sakurai M. CD3-mediated T cell activation is inhibited by anti-CD44 monoclonal antibodies directed to the hyaluronan-binding region. Immunol. Invest. 1999, 28:185-200.
37. Ayala G., Wang D., Wulf G., Frolov A., Li R., Sowadski J., Wheeler T.M., Lu K.P., Bao L. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003, 63:6244-6251.
38. Murad K.L., Gosselin E.J., Eaton J.W., Scott M.D. Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification. Blood 1999, 94:2135-2141.
39. Kahan B.D. Forty years of publication of transplantation proceedings-the second decade: the cyclosporine revolution. Transplant. Proc. 2009, 41:1423-1437.
40. Uchida T., Tomita Y., Anzai K., Zhang Q.W., Yoshikawa M., Kishihara K., Nomoto K., Yasui H. Roles of CD4+ and CD8+ T cells in discordant skin xenograft rejection. Transplantation 1999, 68:1721-1727.
41. Weintraub D., Masek M., Billingham M.E. The lymphocyte subpopulations in cyclosporine-treated human heart rejection. J. Heart Transplant. 1985, 4:213-216.
42. Cranston D., Wood K.J., Carter N.P., Morris P.J. Suppression of allograft rejection in the rat by pretreatment with cells of the T-helper, but not T-cytotoxic suppressor phenotype. Transplant. Proc. 1987, 19:505.
43. Viguier M., Lotteau V., Charron D., Debre P. Xenogeneic recognition of soluble and cell surface HLA class II antigens by proliferative murine T cells. Eur. J. Immunol. 1987, 17:1540-1546.
44. Khan A., Sergio J.J., Zhao Y., Pearson D.A., Sachs D.H., Sykes M. Discordant xenogeneic neonatal thymic transplantation can induce donor-specific tolerance. Transplantation 1997, 63:124-131.
45. McGregor C.G., Davies W.R., Oi K., Teotia S.S., Schirmer J.M., Risdahl J.M., Tazelaar H.D., Kremers W.K., Walker R.C., Byrne G.W., Logan J.S. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J. Thorac. Cardiovasc. Surg. 2005, 130:844-851.